baricitinib

FDA approves new indication for drug to treat severe COVID-19
FDA approves new indication for drug to treat severe COVID-19
Beckers Hospital Review
Eli Lilly
Incyte
baricitinib
FDA
olumiant
COVID-19
Flag link:
Eli Lilly taps 3 Indian drugmakers to bolster supply of COVID-19 drug baricitinib
Eli Lilly taps 3 Indian drugmakers to bolster supply of COVID-19 drug baricitinib
Fierce Pharma
Eli Lilly
baricitinib
India
drug manufacturing
COVID-19
Flag link:
Lilly to seek first approval of an autoimmune drug for hair loss
Lilly to seek first approval of an autoimmune drug for hair loss
BioPharma Dive
Eli Lilly
alopecia areata
baricitinib
clinical trials
Flag link:
Lilly claims promising finding in failed study of COVID-19 drug
Lilly claims promising finding in failed study of COVID-19 drug
BioPharma Dive
Eli Lilly
Incyte
COVID-19
baricitinib
Flag link:
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment
NASDAQ
Eli Lilly
Incyte
baricitinib
alopecia areata
Flag link:
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Yahoo
Eli Lilly
Incyte
baricitinib
atopic dermatitis
EADV
Flag link:
Eli Lilly and Gilead’s combination cuts COVID-19 recovery time
Eli Lilly and Gilead’s combination cuts COVID-19 recovery time
Pharmaforum
Eli Lilly
olumiant
baricitinib
Gilead Sciences
Veklury
remdesivir
COVID-19
clinical trials
NIH
Flag link:
Lilly Has Begun Phase 3 Clinical Trials To See If Its Rheumatoid Arthritis Drug Treats Covid-19
Lilly Has Begun Phase 3 Clinical Trials To See If Its Rheumatoid Arthritis Drug Treats Covid-19
Forbes
Eli Lilly
COVID-19
pandemic
clinical trials
baricitinib
Flag link:
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata
Pharmaceutical Business Review
Eli Lilly
Incyte
breakthrough therapy
FDA
baricitinib
alopecia areata
Flag link:
Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline
Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline
Endpoints
Incyte
olumiant
baricitinib
FDA
Eli Lilly
Flag link:
Lilly's lupus treatment succeeds in mid-stage trial
Lilly's lupus treatment succeeds in mid-stage trial
Reuters
Eli Lilly
lupus
olumiant
baricitinib
clinical trials
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:
Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib
Lilly’s strong Q1 cushions the blow of FDA thumbs-down on high-dose baricitinib
Fierce Pharma
Eli Lilly
earnings
baricitinib
Flag link:
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Safety Concerns Linger for Lilly’s Arthritis Drug as FDA Panel Looms
Xconomy
Eli Lilly
baricitinib
olumiant
rheumatoid arthritis
Flag link:
Positive momentum for biotech Incyte
Positive momentum for biotech Incyte
GoinPharma
Inctye
olumiant
baricitinib
rheumatoid arthritis
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
Could pain data give Lilly's baricitinib back its edge?
Could pain data give Lilly's baricitinib back its edge?
BioPharma Dive
Eli Lilly
baricitinib
Humira
AbbVie
rheumatoid arthritis
Flag link:
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Eli Lilly Preps Rejected Rheumatoid Arthritis Drug for Resubmission
Xconomy
Eli Lilly
rheumatoid arthritis
FDA
baricitinib
Flag link:
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Fierce Pharma
Eli Lilly
baricitinib
Pfizer
Xeljanz
bloodthinners
Flag link:

Pages